deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
docetaxel plus ADT vs. androgen deprivation therapy (ADT) 4 0.76 [0.64; 0.90], 4 RCTs, I2=54% conclusive
unassessable degree of certainty